W. Brissette

发表

Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

J. Hanke, P. Changelian, J. Gardner, 1996, The Journal of Biological Chemistry.

Cultured mesangial cells from autoimmune MRL-lpr mice have decreased secreted and surface M-CSF.

D. Brennan, V. Kelley, A. Jevnikar, 1992, Kidney international.

Analysis of the role of the HIF hydroxylase family members in erythropoiesis.

J. Stock, W. Brissette, D. Perregaux, 2009, Biochemical and biophysical research communications.

Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.

A. Rudensky, J. Stock, J. Mcneish, 1999, Immunity.

Cathepsin S Regulates the Expression of Cathepsin L and the Turnover of γ-Interferon-inducible Lysosomal Thiol Reductase in B Lymphocytes*

A. Rudensky, P. Cresswell, M. Marić, 2001, The Journal of Biological Chemistry.

Destabilizing Role of Cathepsin S in Murine Atherosclerotic Plaques

D. Watkins, W. Brissette, K. Rodgers, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

J. O’Shea, A. Milici, B. Reitz, 2003, Science.

Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.

Christopher S. Poss, M. Hayward, J. Driscoll, 2007, Bioorganic & medicinal chemistry letters.

Effects of continuously administered murine interleukin-1 alpha: tolerance development and granuloma formation

I. Otterness, P. Seymour, W. Brissette, 1989, Infection and immunity.

Novel CCR1 antagonists with improved metabolic stability.

Christopher S. Poss, J. Kath, W. Brissette, 2004, Bioorganic & medicinal chemistry letters.

CP-481,715, a Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases*

Christopher S. Poss, J. Kath, W. Brissette, 2003, Journal of Biological Chemistry.

Combined Use of the JAK3 Inhibitor CP-690,550 with Mycophenolate Mofetil to Prevent Kidney Allograft Rejection in Nonhuman Primates

B. Reitz, D. Ball, Sally Zhang, 2005, Transplantation.

Immunosuppression by the JAK3 Inhibitor CP-690,550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates

B. Reitz, R. Morris, Sally Zhang, 2005, Transplantation.

Identification of erythroid colony progenitors in a subset of human peripheral null lymphocytes devoid of Fc receptors

C. J. Rosenthal, W. Brissette, R. Rieder, 1985, American journal of hematology.

Potent small molecule CCR1 antagonists.

Christopher S. Poss, J. Kath, W. Brissette, 2004, Bioorganic & medicinal chemistry letters.

GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF.

W. Brissette, J. Umland, R. Griffiths, 1995, Cytokine.

Absence of the P2X7 Receptor Alters Leukocyte Function and Attenuates an Inflammatory Response

C. Gabel, L. Audoly, J. Wicks, 2002, The Journal of Immunology.

Increased macrophage colony-stimulating factor in neonatal and adult autoimmune MRL-lpr mice.

D. Brennan, R. P. Wuthrich, W. Brissette, 1991, The American journal of pathology.

Molecular features crucial to the activity of pyrimidine benzamide-based thrombopoietin receptor agonists.

F. Dicapua, M. Munchhof, Y. Abramov, 2008, Bioorganic & medicinal chemistry letters.

Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation

D. Engelman, J. Rogers, L. Gotow, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor.

M. Munchhof, T. Harris, J. Driscoll, 2010, Bioorganic & medicinal chemistry letters.

The identification of orally bioavailable thrombopoietin agonists.

A. Marfat, M. Munchhof, T. Harris, 2009, Bioorganic & medicinal chemistry letters.

Pyrimidine benzamide-based thrombopoietin receptor agonists.

M. Munchhof, J. Driscoll, Jonathan L. Doty, 2007, Bioorganic & medicinal chemistry letters.

The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models

P. Changelian, W. Brissette, M. Conklyn, 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Defects in embryonic development of EGLN1/PHD2 knockdown transgenic mice are associated with induction of Igfbp in the placenta.

Daniel Morton, J. Stock, A. Milici, 2009, Biochemical and biophysical research communications.

Genomic organization of the CC chemokine mip-3alpha/CCL20/larc/exodus/SCYA20, showing gene structure, splice variants, and chromosome localization.

S. McColl, J. Boyd, Ranjeny Thomas, 2001, Genomics.

Genomic organization and biological characterization of the novel human CC chemokine DC-CK-1/PARC/MIP-4/SCYA18.

S. McColl, W. Brissette, K. Neote, 1999, Genomics.

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

M. Hines, M. Munchhof, P. Changelian, 2010, Journal of medicinal chemistry.